免疫联合靶向治疗预防肝细胞癌行ALPPS术后复发的临床疗效

Clinical efficacy of immunotherapy plus target therapy for preventing postoperative recurr-ence of hepatocellular carcinoma after associating liver partition and portal vein ligation for staged hepatectomy

  • 摘要: 原发性肝癌晚期患者手术切除存在因剩余肝脏体积不足,行二步肝癌切除术后早期复发和伴门静脉癌栓发生率高的风险。目前,针对这类患者的治疗手段十分有限,患者的治疗需求无法得到满足。笔者报道1例肝细胞癌剩余肝脏体积不足,行二步肝癌切除术后预防性使用免疫联合靶向治疗的临床经验,旨在为相关治疗提供参考。

     

    Abstract: Surgical resection in patients with advanced primary carcinoma of liver has high risks of early recurrence and incidence of portal vein tumor thrombus, caused by insufficient resi-dual liver volume after two-steps hepatotomy. At present, the treatment for patients with advanced primary carcinoma of liver is limited, thus can't satisfy the requirement of patient for treatment. The authors introduce the clinical experience of a patient with hepatocellular carcinoma and insufficient residual liver volume who underwent preventive immunotherapy plus target therapy after associa-ting liver partition and portal vein ligation for staged hepatectomy, in order to provide reference for relevant treatment.

     

/

返回文章
返回